BRIEF—ABPI code breach by Sanofi

French pharma major Sanofi has breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in, the pharmaceutical industry.

For an article published in a UK Sunday newspaper (that was based on an interview with a Sanofi global senior leader), which promoted Sanofi’s vaccine, Beyfortus (nersevimab-alip), to the public, as well as making misleading claims about Beyfortus and disparaging Pfizer’s vaccine, Sanofi was ruled in breach of the following clauses of the 2024 Code, the trade group noted:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry;